ERBB2 and breast carcinoma: In HER2-directed ADC-resistant breast cancer cell lines, loss of erb-b2 receptor tyrosine kinase 2 (ERBB2) gene amplification, driven by DNA damage and epigenetic mechanisms, further underscores the importance of the DNA repair pathway as both a canonical resistance mechanism and a promising therapeutic target to improve T-DXd efficacy[54].